Natural products have been a great source of leads for cancer drug discovery. The cyclin-dependent kinases (CDKs) play a vital role in the initiation and progression of cancer. The CDK-activating kinase, CDK7/cyclin H/MAT1, has recently gained tremendous attention in targeted cancer drug discovery. Herein, we screened a small library of pure natural products in an ADP-Glo CDK7/H kinase assay that yielded a series of furano- and naphthoflavonoids among actives. Pongol (SBN-88), the hydroxy-substituted furanoflavonoid, inhibits CDK7/H as well as CDK9/T1 with IC values of 0.93 and 0.83 μM, respectively, and >20-fold selectivity over CDK2/E1 (IC > 20 μM). The molecular docking and molecular dynamics simulation revealed that the presence of phenolic -OH in pongol is vital for kinase inhibition, as its absence resulted in a significant loss in activity (e.g., lanceolatin B). The prime MM-GBSA calculations revealed the presence of strong lipophilic and H-bonding interactions of pongol with CDKs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835647 | PMC |
| http://dx.doi.org/10.1021/acsomega.2c06733 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Structural basis of Cdk7 activation by dual T-loop phosphorylation.
Nat Commun
August 2024
Institute of Structural Biology, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Cyclin-dependent kinase 7 (Cdk7) is required in cell-cycle and transcriptional regulation owing to its function as both a CDK-activating kinase (CAK) and part of transcription factor TFIIH. Cdk7 forms active complexes by associating with Cyclin H and Mat1, and is regulated by two phosphorylations in the activation segment (T loop): the canonical activating modification at T170 and another at S164. Here we report the crystal structure of the human Cdk7/Cyclin H/Mat1 complex containing both T-loop phosphorylations.
View Article and Find Full Text PDFStructural basis of Cdk7 activation by dual T-loop phosphorylation.
bioRxiv
February 2024
Institute of Structural Biology, University of Bonn, Venusberg-Campus 1, 53127 Bonn, Germany.
Cyclin-dependent kinase 7 (Cdk7) occupies a central position in cell-cycle and transcriptional regulation owing to its function as both a CDK-activating kinase (CAK) and part of the general transcription factor TFIIH. Cdk7 forms an active complex upon association with Cyclin H and Mat1, and its catalytic activity is regulated by two phosphorylations in the activation segment (T loop): the canonical activating modification at T170 and another at S164. Here we report the crystal structure of the fully activated human Cdk7/Cyclin H/Mat1 complex containing both T-loop phosphorylations.
View Article and Find Full Text PDFDiscovery of Pongol, the Furanoflavonoid, as an Inhibitor of CDK7/Cyclin H/MAT1 and Its Preliminary Structure-Activity Relationship.
ACS Omega
January 2023
Natural Products & Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India.
Natural products have been a great source of leads for cancer drug discovery. The cyclin-dependent kinases (CDKs) play a vital role in the initiation and progression of cancer. The CDK-activating kinase, CDK7/cyclin H/MAT1, has recently gained tremendous attention in targeted cancer drug discovery.
View Article and Find Full Text PDFis a mitotic gene that permits Cdk7 to be fully active as a Cdk-activating kinase.
Development
January 2018
Institute of Cell Biology, Department of Biology, University of Bern, 3012 Bern, Switzerland
encodes a cytosolic iron-sulphur assembly component. We found that is also essential for mitotic divisions and for the proliferation of diploid cells. Reduced activity causes severe mitotic defects in spindle dynamics and chromosome segregation, and loss of zygotic prevents the formation of imaginal discs.
View Article and Find Full Text PDFIbulocydine is a novel prodrug Cdk inhibitor that effectively induces apoptosis in hepatocellular carcinoma cells.
J Biol Chem
June 2011
Division of Pharmaceutical Biosciences, College of Pharmacy, The Research Institute for Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea.
Hepatocellular carcinoma (HCC) is frequently associated with abnormalities in cell cycle regulation, leading to increased activity of cyclin-dependent kinases (Cdks) due to the loss, or low expression of, Cdk inhibitors. In this study, we showed that ibulocydine (an isobutyrate prodrug of the specific Cdk inhibitor, BMK-Y101) is a candidate anti-cancer drug for HCC. Ibulocydine has high activity against Cdk7/cyclin H/Mat1 and Cdk9/cyclin T.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!